Liquid Biopsy-basierte Überwachung der BRCA1-Promoter Hypermethylierung als Therapieresistenz Marker in Brust- und Eierstockkrebs

Advances in liquid biopsy take their claim as indispensable tools in the era of personalized medicine. The detection, monitoring and treatment of cancer patients will be profoundly changed by information that can be obtained with a simple blood draw. The focus here will be on two of the deadliest gynecological cancers: high-grade serous ovarian cancer and triple-negative breast cancer. These two types of cancer share a defect in DNA repair by homologous recombination and may therefore benefit from the same therapy. Clinical examples of breast and ovarian cancer will be discussed to elucidate the potential of monitoring the methylation, and thereby functionality, of the BRCA1 gene in these patients.